Fennec Pharmaceuticals (FENC) Reports In-Line Q1 EPS

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

“We continue our strong momentum across our operations throughout early 2020,” said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. "Following the recent announcement of regulatory submission in the U.S. in February, we were pleased to have been granted Priority Review and a PDUFA date of August 10, 2020. Further, we continue to make progress on our commercial readiness plan in preparation for the potential launch of PEDMARK, if approved, in the second half of 2020. Finally, we significantly strengthened our balance sheet with an over-subscribed follow-on public offering that will allow us to support the commercial launch of PEDMARK and the potential growth period ahead.”

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery